10-Q: Collegium Pharma Reports Q2 Loss Amid Acquisition Integration

Collegium Pharmaceutical, Inc. reported a net loss for the quarter ended June 30, 2026, with revenues increasing due to the Azstarys acquisition, while operating expenses also rose significantly.

Summary

• Collegium Pharmaceutical, Inc. reported a net loss of $15.1 million for the three months ended June 30, 2026, compared to a net income of $12.0 million in the same period of 2025.
• Total revenues increased to $199.9 million for the three months ended June 30, 2026, up from $188.0 million in the prior year period, driven by growth in Jornay PM, Azstarys, and Belbuca.
• Selling, general, and administrative expenses increased by $33.0 million to $106.6 million, largely due to $23.2 million in acquisition-related expenses for Azstarys and increased salaries, wages, and benefits.
• The company's cash and cash equivalents stood at $129.5 million as of June 30, 2026.
• The Azstarys acquisition, completed in May 2026, contributed $12.9 million in revenue for the period.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to a net loss and increased operating expenses, despite revenue growth driven by recent acquisitions.

Positives

• Product revenues increased by $11.9 million to $199.9 million for the three months ended June 30, 2026, compared to $188.0 million in the prior year period.
• Jornay PM revenue increased by $13.4 million, Azstarys revenue increased by $12.9 million (post-acquisition), and Belbuca revenue increased by $5.1 million.
• Adjusted EBITDA increased by $8.7 million to $113.8 million for the three months ended June 30, 2026, compared to $105.1 million in the prior year period.
• The company has $129.5 million in cash and cash equivalents as of June 30, 2026, which management believes is sufficient for future operations.

Negatives

• The company reported a net loss of $15.1 million for the three months ended June 30, 2026, a significant decrease from a net income of $12.0 million in the same period of 2025.
• Selling, general, and administrative expenses increased by $33.0 million to $106.6 million, primarily due to acquisition-related expenses and increased personnel costs.
• Intangible asset amortization increased by $7.5 million due to the Azstarys acquisition.
• The effective tax rate for the three months ended June 30, 2026, was negative at (11.2)%, compared to 29.6% in the prior year period, reflecting the net loss.

Risks

• The company has substantial outstanding indebtedness, including $865.5 million under the 2025 Term Loan and $241.5 million in 2029 Convertible Notes.
• Failure to successfully integrate the Azstarys acquisition could lead to unexpected costs and delays.
• Ongoing litigation related to opioid medications and patent infringement could result in significant costs and adverse outcomes.
• The company relies on third-party manufacturers, and any production issues or supply chain disruptions could materially affect its business.
• Changes in healthcare laws and regulations, including pricing and reimbursement policies, could adversely affect the company's business.
• The market price of common stock is volatile and subject to significant fluctuations.

Future Outlook

The company believes its current cash and cash equivalents, along with expected cash inflows from operations, will be sufficient to fund its operating expenses, debt service, and capital expenditure requirements under its current business plan for the foreseeable future. However, it acknowledges significant future capital requirements and potential risks associated with its business.

Management Comments

• The company is a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions.
• The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain.
• The company believes that its cash and cash equivalents as of June 30, 2026, together with expected cash inflows from operations, will enable it to fund its operating expenses, debt service, and capital expenditure requirements under its current business plan for the foreseeable future.

Industry Context

StockSavvy.ai notes that Collegium operates in the competitive biopharmaceutical sector, focusing on ADHD and pain management. The recent acquisition of Azstarys positions the company to capitalize on the growing ADHD market, but also increases operational complexity and expenses, a common challenge in industry consolidation.

Comparison to Industry Standards

• The company's revenue growth of approximately 6.3% for the quarter is in line with or slightly below the average growth rates seen in the specialty pharmaceutical sector, which can vary significantly based on product lifecycle and market penetration.
• The significant increase in SG&A expenses, driven by acquisition costs, is a common trend for companies undergoing M&A activity, impacting short-term profitability.
• The company's net loss, while concerning, is not uncommon for biopharmaceutical companies investing heavily in product commercialization and acquisitions, especially when integrating new assets.

Legal Proceedings

• Ongoing patent infringement litigation concerning Xtampza ER and Nucynta Products.
• Litigation related to the BDSI Acquisition alleging material omissions in disclosures.
• Patent infringement lawsuit filed by Ascent Pharmaceuticals concerning Belbuca.
• Arbitration with David Lickrish (assignee of North Sound Pharmaceuticals) related to pre-acquisition acts.
• Lawsuit filed by Walgreen Co. regarding product returns credits.
• Opioid-related investigations and potential litigation from state attorneys general and third-party payors.

Stakeholder Impact

• Shareholders may experience volatility in stock price due to the net loss and increased expenses.
• Employees may be affected by executive transitions and integration of acquired personnel.
• Customers and payors will continue to interact with the company's expanded product portfolio, including Azstarys.

Next Steps

• Continue to integrate Azstarys operations to realize anticipated benefits.
• Manage outstanding indebtedness and comply with covenants under credit agreements.
• Defend vigorously against ongoing litigation, including patent infringement and opioid-related matters.
• Continue to commercialize and grow sales of its product portfolio, including Jornay PM and Azstarys.

Key Dates

Recommendation

While revenue growth is positive, the net loss, significant increase in operating expenses due to acquisitions, and ongoing legal challenges suggest a cautious approach. The company's ability to integrate Azstarys effectively and manage its debt load will be critical for future performance. A 'hold' recommendation reflects the mixed financial results and the inherent risks in the biopharmaceutical sector.

Keywords

Collegium Pharmaceutical, Azstarys, Jornay PM, ADHD, Pain Management, Biopharmaceutical, SEC Filing, 10-Q